The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeted-sequencing in rare cancers and the impact on patient treatment.
 
Hitomi Sumiyoshi Okuma
No Relationships to Disclose
 
Takashi Kubo
No Relationships to Disclose
 
Hitoshi Ichikawa
No Relationships to Disclose
 
Takashi Kohno
Research Funding - Daiichi Sankyo; Sysmex
 
Takaaki Mizuno
No Relationships to Disclose
 
Yuki Kojima
No Relationships to Disclose
 
Kuniko Sunami
No Relationships to Disclose
 
Akihiko Shimomura
Honoraria - AstraZeneca; Chugai Pharma; Eisai; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Lilly Japan
Research Funding - Novartis (Inst)
 
Satoru Iwasa
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Otsuka (Inst)
 
Shunsuke Kondo
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer (Inst); Lilly (Inst); MSD (Inst); Pfizer (Inst)
 
Yutaka Fujiwara
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst)
 
Kan Yonemori
Honoraria - Eisai; Taiho Pharmaceutical
Consulting or Advisory Role - Eisai
 
Kenji Tamura
No Relationships to Disclose
 
Noboru Yamamoto
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - ASLAN Pharmaceuticals; Boehringer Ingelheim; Eisai; OncoTherapy Science; Otsuka; Takeda
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQVIA (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)